Aquablation® Therapy Recommended in 2020 European Association of Urology Guidelines for the Management of Non-Neurogenic Male LUTS

San Francisco, CA (UroToday.com) --  PROCEPT® BioRobotics, a surgical robotics company developing intelligent solutions to transform the field of urology, announced today that the European Association of Urology (EAU) has amended its 2020 guidelines to include a formal recommendation for Aquablation® therapy as a treatment option for males with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).

The revised EAU Non-Neurogenic Male LUTS Guidelines state that “Aquablation therapy may be offered to patients with moderate-to-severe LUTS and prostates between 30 and 80 mL as an alternative to transurethral resection of the prostate (TURP).” The new guidelines apply to men aged 40 years or older who seek professional help for LUTS in various non-neurogenic and non-malignant conditions such as LUTS/Benign Prostatic Obstruction (BPO), detrusor overactivity/overactive bladder (OAB) or nocturnal polyuria. 

“Aquablation therapy has been providing relief to patients in Europe since 2017. The inclusion of our therapy in the EAU guidelines is a critical milestone for patients and physicians throughout Europe,” said Reza Zadno, PROCEPT BioRobotics president and chief executive officer.
“Currently part of the American and Canadian guidelines, Aquablation therapy’s inclusion in the European guidelines further validates the clinical value of this procedure, allowing Aquablation therapy to effectively fill the existing treatment void of a durable, resective treatment that has a minimal risk of irreversible complications, including sexual side effects.” 

The EAU Non-Neurogenic Male LUTS Guidelines Panel consists of an international group of experts with urological and clinical epidemiological backgrounds. The addition of Aquablation therapy was based on the review of new and relevant clinical studies representing high levels of evidence, including systematic reviews with meta-analysis, randomized controlled trials (RCTs), and prospective non-randomized comparative studies.

The EAU recommendation follows the addition of Aquablation therapy to the 2019 American Urological Association (AUA) surgical practice guidelines as a standard of care treatment for male LUTS due to an enlarged prostate, the 2018 Canadian Urology Association (CUA) guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH), and the 2018 National Institute for Health and Care Excellence (NICE) Interventional Procedure Guidance for lower urinary tract symptoms. 

Aquablation therapy is available in the U.S., Canada, the UK, Europe, the Middle East, and Asia.

About the EAU 

For almost 40 years the EAU has addressed the most pressing issues of urological care in Europe, through its scientific and educational initiatives, as well as its publications. Guidelines development is one of the core activities of the EAU as part of their educational efforts. The current corpus of available guidelines covers most of the urological field. The aim of the EAU Guidelines is to assist practicing clinicians in making informed decisions in a given circumstance; taking the highest quality scientific data, their patient’s personal circumstances, values, and preferences into account. https://uroweb.org/guidelines/

Source: "Aquablation® Therapy Recommended In 2020 European Association Of Urology Guidelines For The Management Of Non-Neurogenic Male LUTS | Biospace". 2020. Biospace